Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 5/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498412 | 0.84 | WNT3A (0.52) | WNT3AAOC3ADRA1AMEN1KMT2A | |
| SCHEMBL10254779 | 0.82 | AOC3 (0.54) | AOC3CNR2OPRM1CYP11B1CYP11B2 | |
| SCHEMBL31369460 | 0.81 | WNT3A (0.53) | WNT3AAOC3 | |
| SCHEMBL12675278 | 0.81 | HTR3A (0.47) | AOC3KMT2A | |
| SCHEMBL23683824 | 0.81 | WNT3A (0.64) | WNT3AAOC3ADRA1AACHE | |
| SCHEMBL10254758 | 0.80 | AOC3 (0.55) | AOC3CNR2 | |
| Hydrochloric Acid SCHEMBL5010436 | 0.80 | AOC3 (0.52) | AOC3CNR2OPRM1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL5009806 | 0.79 | HTR3A (0.46) | AOC3KMT2A | |
| Hydrochloric Acid SCHEMBL5008435 | 0.79 | AOC3 (0.53) | AOC3CNR2OPRM1 | |
| SCHEMBL2253910 | 0.79 | GRIN2D (0.49) | WNT3AADRA1ACNR2OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | WNT3A, WNT1, WNT3 | WNT3A 1/4885AOC3 4525/4885ADRA1A 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.